Aeterna Jumps on FDA Fast-Track Status Request: Montreal Mover

Aeterna Zentaris Inc. (AEZ) rose the most in almost three weeks after the biotech company said it would ask the U.S. Food and Drug Administration to fast-track the approval process for its proposed test to diagnose growth hormone deficiency.

Aeterna, based in Quebec City, jumped 7 percent to 46 Canadian cents by 4 p.m. in Toronto, its largest single-day gain since July 5.

The FDA is due to respond to the request within 60 days, Aeterna said today in a statement. Aeterna expects to complete its submission for the AEZS-130 diagnostic test in the first quarter of 2013 if the FDA grants fast-track status, the company said.

To contact the reporter on this story: Frederic Tomesco in Montreal at tomesco@bloomberg.net

To contact the editor responsible for this story: Ed Dufner at edufner@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.